184MO First-in-human phase I/IIa study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 in combination with endocrine therapy (ET) in patients (pts) with HR+/HER2− metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors (CDK4/6i): Safety and efficacy update
Yap T, Sharma M, Hamilton E, Lorusso P, Basu C, Delioukina M, Liu F, Neumann H, Park J, Giordano A. 184MO First-in-human phase I/IIa study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 in combination with endocrine therapy (ET) in patients (pts) with HR+/HER2− metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors (CDK4/6i): Safety and efficacy update. ESMO Open 2024, 9: 103206. DOI: 10.1016/j.esmoop.2024.103206.Peer-Reviewed Original Research